HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

771.365

-7.978-1.02%

Number of Gainers:11

Number of Losers:21

Number of Flat:2

PE:- -

High:787.307

Open:779.323

Low:769.906

Close:779.344

Loading ...

Ascletis Pharma Completes Enrollment in Obesity Drug Study in the US

MT Newswires Live

Venus Medtech Hangzhou Inc - Legal Victory for Cardiovalve Against Edwards Lifesciences

THOMSON REUTERS

Zhaoke Ophthalmology Gets Registration Certificate for Tonometer in China

MT Newswires Live

Acotec Scientific Gets China Registration Nod for Dilatation Catheter

MT Newswires Live

37 New Funds Launch This Week: Targeting STAR Market + Medicine and Other Hot Sectors, with Liu Shiqing, Tian Guangyuan, Deng Mo, En Xuehai and Others in Competition

Acotec Scientific Holdings Ltd. Receives PRC Approval for Sirolimus-Coated Coronary Balloon Dilatation Catheter AcoArt Canna®

BRIEF-Zhaoke Ophthalmology Obtains Registration For Tono-I Device From NMPA

CStone Pharmaceuticals Announces Upcoming Board Meeting to Review Interim Results and Potential Interim Dividend

ACOTEC-B (06669): China NMPA Approves Registration of Sirolimus Drug-Coated Coronary Balloon Catheter AcoArt Canna®

Acotec Scientific - PRC Nmpa Approves Sirolimus-Coated Coronary Balloon Dilatation Catheter Acoart Canna

THOMSON REUTERS

ZHAOKE OPHTH-B (06622) Obtains Medical Device Registration Certificate from NMPA for TONO-i Eye Pressure Measurement Device

Zhaoke Ophthalmology - Obtains Registration for Tono-I Device From Nmpa

THOMSON REUTERS

GAUSH MEDITECH (02407): "Frequency Domain Biometer" Receives Medical Device Registration Certificate in China

Guotai Haitong Securities: 2025 Marks Commercialization Year for Domestic Weight-Loss Innovative Drugs, Related Companies Face Multiple Catalysts Ahead

Everest Medicines Subscribes for 15.8 Million ADSs in Global Biotech Firm; Shares Jump 8%

MT Newswires Live

AH Stock Statistics | August 4th

Apichope Pharmaceutical Group (300723.SZ) Subsidiary Receives Clinical Trial Application Acceptance for Innovative Drug APH03621 Tablet

Akeso Inc. Receives Approval from NMPA and FDA to Initiate Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant Hepatocellular Carcinoma

Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (Pd-1/Ctla-4) for Pd-1 Treatment-Resistant Hepatocellular Carcinoma

THOMSON REUTERS

Alphamab Oncology's IND Application for Innovative Cancer Drug JSKN022 Accepted by China's CDE

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":771.3654,"timestamp":1754451381676,"preClose":779.34357,"halted":0,"volume":96159950,"delay":0,"changeRate":-0.010237,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-7.978149,"latestTime":"08-06 11:36:22","open":779.3232,"high":787.30676,"low":769.9058,"amount":2941503031,"amplitude":0.022328,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1754452800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1754443800000,1754452800000],[1754456400000,1754467200000]],"pbRate":6.257988,"peRate":-38.540364,"turnoverRate":0.003622,"increases":11,"decrements":21,"flats":1,"marketCap":453324060096,"floatMarketCap":419204005280},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":787.30676,"amplitude":0.022328,"preClose":779.34357,"low":769.9058,"pbRate":"6.257988","latestPrice":771.3654,"volume":96159950,"delay":0,"open":779.3232,"prevYearClose":331.1933,"prevWeekClose":721.922,"prevMonthClose":735.033,"prevQuarterClose":555.617,"fiveDayClose":749.189,"twentyDayClose":599.897,"sixtyDayClose":447.877,"secType":"PLATE","market":"HK","turnoverRate":0.003622,"peRate":-38.540364,"marketCap":453324060096,"floatMarketCap":419204005280,"timestamp":1754451381676,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":11,"down":21,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557315997","title":"Ascletis Pharma Completes Enrollment in Obesity Drug Study in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2557315997","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557315997?lang=en_us&edition=fundamental","pubTime":"2025-08-05 20:45","pubTimestamp":1754397924,"startTime":"0","endTime":"0","summary":"Ascletis Pharma (HKG:1672) completed enrollment in a phase IIa study in the US evaluating ASC30 for the treatment of obesity, a Tuesday Hong Kong bourse filing said.All 125 participants of the study are obese or overweight with at least one weight-related comorbidity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01672","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2557150399","title":"Venus Medtech Hangzhou Inc - Legal Victory for Cardiovalve Against Edwards Lifesciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2557150399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557150399?lang=en_us&edition=fundamental","pubTime":"2025-08-05 20:16","pubTimestamp":1754396192,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nFWN3TX1BO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02500","BK1583","BK1574","BK1100"],"gpt_icon":0},{"id":"2556811387","title":"Zhaoke Ophthalmology Gets Registration Certificate for Tonometer in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2556811387","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556811387?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:21","pubTimestamp":1754310065,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology (HKG:6622) obtained a medical device registration certificate for TONO-i from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.TONO-i is a tonometer designed to be contactless, portable, and convenient.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06622","BK1587","BK1583","BK1191"],"gpt_icon":0},{"id":"2556820387","title":"Acotec Scientific Gets China Registration Nod for Dilatation Catheter","url":"https://stock-news.laohu8.com/highlight/detail?id=2556820387","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556820387?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:18","pubTimestamp":1754309898,"startTime":"0","endTime":"0","summary":"Acotec Scientific  obtained registration approval for the sirolimus-coated coronary balloon dilatation catheter AcoArt Canna from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.AcoArt Cannais indicated for the dilatation treatment of de novo coronary artery bifurcation lesions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06669","BK1100","BK1587","BK1574"],"gpt_icon":0},{"id":"1120443068","title":"37 New Funds Launch This Week: Targeting STAR Market + Medicine and Other Hot Sectors, with Liu Shiqing, Tian Guangyuan, Deng Mo, En Xuehai and Others in Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=1120443068","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120443068?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:32","pubTimestamp":1754307150,"startTime":"0","endTime":"0","summary":"On August 4th, 37 new funds are launching this week, involving 27 fund companies including China Asset Management, E Fund Management, GF Fund Management, Southern Fund, Harvest Fund, Fuguo Fund,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159982","159938","BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2556214388","title":"Acotec Scientific Holdings Ltd. Receives PRC Approval for Sirolimus-Coated Coronary Balloon Dilatation Catheter AcoArt Canna®","url":"https://stock-news.laohu8.com/highlight/detail?id=2556214388","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556214388?lang=en_us&edition=fundamental","pubTime":"2025-08-04 18:40","pubTimestamp":1754304028,"startTime":"0","endTime":"0","summary":"Acotec Scientific Holdings Ltd. has announced that it has received registration approval from the PRC National Medical Products Administration for its Sirolimus-Coated Coronary Balloon Dilatation Catheter, AcoArt Canna. This approval marks a significant milestone for the company, allowing it to proceed with marketing activities in the PRC market when deemed appropriate. The AcoArt Canna is designed for the dilatation treatment of de novo coronary artery bifurcation lesions with vessel diameters ranging from 2.0mm to 4.0mm. Clinical trials have demonstrated its efficacy and safety, with no statistically significant difference in diameter stenosis compared to the control group using paclitaxel-coated catheters. However, the company cautions that it may not ultimately be able to market the product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL76sBGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","LU2265009873.SGD","LU1291159041.SGD","LU2506951958.HKD","LU1791710400.SGD","LU0238689110.USD","LU1720051108.HKD","BK4588","LU1548497426.USD","IE00BJJMRZ35.SGD","LU0187121727.USD","LU0225283273.USD","LU1366192091.USD","BK4581","LU2491049909.HKD","LU0823416689.USD","IE00B2B36J28.USD","LU0882574055.USD","LU0345769631.USD","LU0266013472.USD","LU1983299246.USD","SG9999013999.USD","LU1989772923.USD","LU0345769128.USD","LU2362541513.USD","BK1587","IE00B4R5TH58.HKD","LU0823417737.USD","IE0002141913.USD","LU2242649171.HKD","BSX","LU0011850046.USD","LU0267386448.USD","LU0048584097.USD","SGXZ57979304.SGD","BK1574","06669","LU0353189763.USD","LU0950375773.USD","LU2244417387.USD","LU2087625088.SGD","LU0122379950.USD","LU1989771016.USD","LU2362541273.HKD","IE00BJT1NW94.SGD","SG9999001176.SGD","LU2506952097.USD","LU2506952170.USD","IE00BFTCPJ56.SGD","LU2112291526.USD"],"gpt_icon":0},{"id":"2556884303","title":"BRIEF-Zhaoke Ophthalmology Obtains Registration For Tono-I Device From NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2556884303","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556884303?lang=en_us&edition=fundamental","pubTime":"2025-08-04 18:37","pubTimestamp":1754303866,"startTime":"0","endTime":"0","summary":"BRIEF-Zhaoke Ophthalmology Obtains Registration For Tono-I Device From NMPAAug 4 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK:OBTAINS REGISTRATION FOR TONO-I DEVICE FROM NMPAFurther company coverage: 6622.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nFWN3TW0PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","BK1574","06622","BK1191"],"gpt_icon":0},{"id":"2556388687","title":"CStone Pharmaceuticals Announces Upcoming Board Meeting to Review Interim Results and Potential Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2556388687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556388687?lang=en_us&edition=fundamental","pubTime":"2025-08-04 18:26","pubTimestamp":1754303195,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals has announced that its Board of Directors will hold a meeting on Thursday, August 14, 2025. The meeting's agenda includes considering and approving the unaudited interim results of the company and its subsidiaries for the six months ended June 30, 2025, and discussing the payment of an interim dividend, if applicable.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief on August 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL5jNDNm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"1123678645","title":"ACOTEC-B (06669): China NMPA Approves Registration of Sirolimus Drug-Coated Coronary Balloon Catheter AcoArt Canna®","url":"https://stock-news.laohu8.com/highlight/detail?id=1123678645","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123678645?lang=en_us&edition=fundamental","pubTime":"2025-08-04 18:20","pubTimestamp":1754302825,"startTime":"0","endTime":"0","summary":"ACOTEC-B (06669) announced that on July 31, 2025, the company received registration approval from China's National Medical Products Administration for its sirolimus drug-coated coronary balloon...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","BK1100","06669"],"gpt_icon":0},{"id":"2556280090","title":"Acotec Scientific - PRC Nmpa Approves Sirolimus-Coated Coronary Balloon Dilatation Catheter Acoart Canna","url":"https://stock-news.laohu8.com/highlight/detail?id=2556280090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556280090?lang=en_us&edition=fundamental","pubTime":"2025-08-04 18:13","pubTimestamp":1754302387,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nFWN3TW01T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06669","BK1574","BK1100","BK1587"],"gpt_icon":0},{"id":"1120166434","title":"ZHAOKE OPHTH-B (06622) Obtains Medical Device Registration Certificate from NMPA for TONO-i Eye Pressure Measurement Device","url":"https://stock-news.laohu8.com/highlight/detail?id=1120166434","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120166434?lang=en_us&edition=fundamental","pubTime":"2025-08-04 17:50","pubTimestamp":1754301028,"startTime":"0","endTime":"0","summary":"ZHAOKE OPHTH-B (06622) announced that the company has obtained a medical device registration certificate from the National Medical Products Administration (NMPA) for TONO-i. TONO-i is an innovative...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06622","159883","BK1587","BK1583","BK1222","09997","09996","BK1100","BK1191"],"gpt_icon":0},{"id":"2556807601","title":"Zhaoke Ophthalmology - Obtains Registration for Tono-I Device From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2556807601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556807601?lang=en_us&edition=fundamental","pubTime":"2025-08-04 17:45","pubTimestamp":1754300758,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nFWN3TW0PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1587","06622","BK1574","BK1191"],"gpt_icon":0},{"id":"1150899865","title":"GAUSH MEDITECH (02407): \"Frequency Domain Biometer\" Receives Medical Device Registration Certificate in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1150899865","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150899865?lang=en_us&edition=fundamental","pubTime":"2025-08-04 17:40","pubTimestamp":1754300422,"startTime":"0","endTime":"0","summary":"GAUSH MEDITECH (02407) announced that its subsidiary, Gaush Innovation Technology Co., Ltd. (Gaush Innovation), has recently obtained a medical device registration certificate for its \"Frequency...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","09997","09996","159883","BK1222","BK1583","02407"],"gpt_icon":0},{"id":"1111049469","title":"Guotai Haitong Securities: 2025 Marks Commercialization Year for Domestic Weight-Loss Innovative Drugs, Related Companies Face Multiple Catalysts Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=1111049469","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111049469?lang=en_us&edition=fundamental","pubTime":"2025-08-04 16:38","pubTimestamp":1754296724,"startTime":"0","endTime":"0","summary":"According to Zhitong Finance APP, Guotai Haitong Securities has released a research report stating that 2025 represents the commercialization year for domestically-produced weight-loss innovative...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06978","BK0276","BK0183","BK1564","BK0188","159992","BK0184","02611","BK0028","601211","BK1574","BK1147","BK0012","BK0201"],"gpt_icon":0},{"id":"2556809610","title":"Everest Medicines Subscribes for 15.8 Million ADSs in Global Biotech Firm; Shares Jump 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556809610","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556809610?lang=en_us&edition=fundamental","pubTime":"2025-08-04 16:18","pubTimestamp":1754295512,"startTime":"0","endTime":"0","summary":"Everest Medicines  subscribed for over 15.8 million American depositary shares  in Nasdaq-listed global biotech firm, I-Mab, for $30.9 million or $1.95 apiece, an Aug. 1 Hong Kong bourse filing said.Shares of the drug company rose over 8% in Monday afternoon trading.10 ADSs in I-Mab represent 23 ordinary shares of the firm.Following completion, Everest Medicines holds 15.8 million ADSs and nearly 6.1 million ordinary shares in I-Mab, representing 16.1% of the latter's enlarged issued share capital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01952","MDCO","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"1101900513","title":"AH Stock Statistics | August 4th","url":"https://stock-news.laohu8.com/highlight/detail?id=1101900513","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101900513?lang=en_us&edition=fundamental","pubTime":"2025-08-04 16:16","pubTimestamp":1754295402,"startTime":"0","endTime":"0","summary":"As of the close on August 4th, NE ELECTRIC (00042), HOLLY FUTURES (03678), and SINOPEC SSC (01033) ranked as the top three stocks by AH premium rate, with rates of 831.03%, 243.94%, and 213.16%...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","LU0589944569.HKD","SG9999004220.SGD","00300","01812","IE00BF5LJ272.USD","01276","LU0287142896.SGD","LU1048596156.SGD","06680","SG9999002463.SGD","LU0456827905.SGD","02899","LU0370786039.SGD","LU0140636845.USD","LU0502904849.HKD","LU0181495838.USD","BK1592","LU1770034418.SGD","BK1551","LU0593848301.USD","06185","LU0431992006.USD","01288","LU0890818403.SGD","LU0348825331.USD","LU1808992512.USD","LU0348788117.USD","LU2125910500.SGD","LU0540923850.HKD","02628","03606","BK1546","BK1161","LU0455707207.USD","LU2226246903.HKD","SG9999014674.SGD","LU0061477393.USD","LU0320764599.SGD","LU0307460666.USD","LU0648948544.HKD","06806","LU1303224171.USD","BK1237","LU0821914370.USD","LU1282649067.USD","LU1880383366.USD","LU0327786744.USD","LU0384037296.USD","LU2399975544.HKD","LU1282649141.HKD","LU1675838814.USD","SG9999012710.SGD","LU0828238088.HKD","LU0348816934.USD","LU1688375341.USD","BK1583","IE00BYV24P56.USD","LU0173614495.USD","IE00BZ08YT58.USD","LU0543330566.HKD","BK1515","LU0051755006.USD","LU0269904917.USD","LU0244354667.USD","LU0634319403.HKD","03143","LU0588546209.SGD","01456","LU1880383440.USD","LU0797268264.HKD","HK0000306685.HKD","IE0034224299.USD","SG9999012728.SGD","SG9999006597.SGD","IE00B0169L03.USD","02218","LU0516422366.SGD","LU0708995583.HKD","IE00B5MMRT66.SGD","BK1554","LU1242518857.USD","06127","BK1539","BK1191","IE00B3M56506.USD","BK1514","LU0067412154.USD","LU0516423174.USD","LU0228659784.USD","LU1794554557.SGD","LU2476274720.SGD","LU0488056044.USD","03750","IE00B031HY20.USD","LU0229945570.USD","BK1584","02465","BK1171","BK1231","LU0348814723.USD","LU1152091754.HKD","06881","01033","LU1023057109.AUD","LU0979878070.USD","LU2039709279.SGD","LU1242518931.SGD","LU0561508036.HKD","IE00BVYPNP33.GBP","02359","LU0516422952.EUR","LU1226287529.USD","BK1144","LU0052750758.USD","LU1282649810.SGD","BK1521","BK1560","LU0516423091.SGD","LU1960683339.HKD","LU0231483743.USD","01057","BK1562","LU0862451753.SGD","03968","BK1550","LU0348735423.USD","LU0106959298.USD","LU1961090484.USD","HK0000320223.HKD","LU1504937902.USD","LU1046422090.SGD","02611","SG9999012744.USD","IE00BZ08YS42.EUR","LU0828237940.HKD","LU0048580855.USD","00588","BK1240","LU1188198961.HKD","LU1719994722.HKD","LU0640798160.USD","IE0032431581.USD","LU2476274308.USD","LU1251922891.USD","LU0072913022.USD","HK0000306701.USD","LU0823426480.USD","LU1152091168.USD","LU0345780281.USD","LU0828237510.HKD","00042","LU1831875114.USD","LU0096374516.USD","BK1522","LU0417516738.SGD","BK1183","LU0348805143.USD","LU0880133367.SGD","SG9999002828.SGD","BK1119","LU0463099449.HKD","BK1576","LU1008478684.HKD","LU1993786604.SGD","IE00B29SXG58.USD","LU0359202008.SGD","BK1574","02039","HK0000320264.USD","01349","LU2097828474.EUR","LU2097828557.USD","LU0516422440.USD","BK1223","399300","LU0314109678.HKD","LU0359201612.USD","LU0918141705.HKD","IE0008368742.USD","LU1813983027.USD","03678","LU0868486357.SGD","IE00BGHQDM52.EUR","BK1205","LU0315179316.USD","01375","IE00BZ08YR35.GBP","02338","LU0345780521.USD","LU0501845795.SGD","BK1564","LU2097828631.EUR","BK1509","159982","IE00BMCWC346.EUR","LU0918141887.USD","LU0572944931.SGD","LU1282648689.USD","BK1184","LU0509642566.USD","LU1105468828.SGD","LU2242644610.SGD","BK1507","LU1224709979.USD","BK1198","LU0326950275.SGD","LU1115378108.SGD","LU0348827113.USD","BK1147","LU1807302812.USD","BK1141","BK1505","LU0417516902.SGD","06693","LU2097828805.USD","BK1214","IE0031814852.USD","LU0163747925.USD","LU0823426308.USD","LU0456846285.SGD","LU1328277881.USD","02238","LU2778985437.USD","IE00BVYPNQ40.USD","LU0228367735.SGD","LU0469268626.HKD","LU1211504680.USD","00187","BK1116","LU0737861699.HKD","LU1720050803.USD","SG9999012736.USD","LU2045819591.USD","LU1655091616.SGD","BK1594","IE00B031J352.USD","BK1610","LU0886674414.USD","LU2097828714.EUR","BK1110","BK1544","02727","IE00B543WZ88.USD","BK1202"],"gpt_icon":1},{"id":"1122507383","title":"Apichope Pharmaceutical Group (300723.SZ) Subsidiary Receives Clinical Trial Application Acceptance for Innovative Drug APH03621 Tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1122507383","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122507383?lang=en_us&edition=fundamental","pubTime":"2025-08-04 16:08","pubTimestamp":1754294900,"startTime":"0","endTime":"0","summary":"Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) announced that its wholly-owned subsidiary Guangzhou Apichope Pharmaceutical Co., Ltd. has received acceptance from the National Medical Products...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK0239","06978","300723","159992","BK1574"],"gpt_icon":0},{"id":"2556088858","title":"Akeso Inc. Receives Approval from NMPA and FDA to Initiate Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2556088858","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556088858?lang=en_us&edition=fundamental","pubTime":"2025-08-04 13:57","pubTimestamp":1754287025,"startTime":"0","endTime":"0","summary":"Akeso Inc. Receives Approval from NMPA and FDA to Initiate Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant Hepatocellular Carcinoma. Akeso Inc., a biotechnology company, has announced the approval to initiate a global, multicenter, randomized Phase II registrational trial for their PD-1/CTLA-4 bispecific antibody, cadonilimab. The trial, known as COMPASSION-36/AK104-225, has received regulatory clearance from both China's National Medical Products Administration  and the U.S. Food and Drug Administration . This trial will evaluate the efficacy of cadonilimab in combination with lenvatinib versus lenvatinib alone in treating advanced hepatocellular carcinoma  in patients who have previously been treated with atezolizumab and bevacizumab. This approval marks a significant step for Akeso in addressing the global challenge of cancer immunotherapy resistance and advancing treatment options for patients with limited survival benefits from current therapies.Disclaimer:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL9v0D8m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","IE00B543WZ88.USD","LU1794554557.SGD","LU0417516571.SGD","LU0348783233.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU1720050803.USD","IE00B5MMRT66.SGD","09926"],"gpt_icon":0},{"id":"2556870071","title":"Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (Pd-1/Ctla-4) for Pd-1 Treatment-Resistant Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2556870071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556870071?lang=en_us&edition=fundamental","pubTime":"2025-08-04 13:56","pubTimestamp":1754287003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nTUA5KFSYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0348783233.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU1720050803.USD","LU2488822045.USD","LU0348784397.USD","BK1161","LU1794554557.SGD","09926"],"gpt_icon":0},{"id":"2556827978","title":"Alphamab Oncology's IND Application for Innovative Cancer Drug JSKN022 Accepted by China's CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=2556827978","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556827978?lang=en_us&edition=fundamental","pubTime":"2025-08-03 18:17","pubTimestamp":1754216239,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has announced that their Investigational New Drug  application for JSKN022 has been officially accepted by the Center for Drug Evaluation  of the National Medical Products Administration of China. JSKN022 is an innovative bispecific antibody-drug conjugate targeting programmed death ligand 1  and integrin αvβ6, developed independently by Alphamab. This marks a significant step forward as there are currently no approved ADCs targeting integrin αvβ6 or PD-L1 globally. The company plans to commence a first-in-human clinical study for treating advanced malignant solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief on August 03, 2025,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250803:nNDL1TmR4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":112,"code":"91000000","status":"200"}]}}